Kernal Biologics; a Cambridge, Massachusetts-based company, was founded by Yusuf Erkul, Burak Yilmaz, and Cafer Ozdemir in 2016.
Kernal is a synthetic biology company developing onco-selective messenger RNA (mRNA) for cancer immunotherapies. Additionally, Kernal utilizes deep learning methods to further research and drug development. By employing codon-engineering in therapeutic development, Kernal is looking to empower specific cells, within the human body, to create their own treatments and medicine as a cancer treatment.
In 2019, Kernal Biologics was accepted into the Spring MassBio's MassCONNECT, a two month mentorship program where industry experts educate and lead entrepreneurs to better develop their business plan, launch, and raising capital. This process allows leading experts to identify strengths, weaknesses, opportunities, and threats to the young companies.
Kernal Biologics began creating immunotherapy for COVID-19 after the mass outbreak in early 2020 by leveraging deep learning and synthetic biology.
Documentaries, videos and podcasts
- Cluster: RNA-based and RNA-targeted therapeuticsA cluster of topics related to RNA-based therapeutics and RNA-targeted therapeutics. RNA-based therapeutics include RNA and oligonucleotide therapeutics that target RNA and proteins. RNA-targeted therapeutics include RNA and oligonucleotide therapeutics as well as small molecule drugs that target RNA.